Responsibility at the Forefront of Innovation

At Cognigenics, we approach neurogenetic innovation with a firm ethical framework:

• We adhere to all relevant FDA, EMA, and AAALAC guidelines for preclinical and clinical work.
• All animal studies are conducted under approved IACUC protocols, ensuring humane, justified use.
• Our intranasal delivery system is designed to minimize patient burden, support autonomy, and eliminate unnecessary systemic exposure.

As we develop the world’s first psychiatric siRNA platform, we remain committed to transparency, safety, and patient-centered design.

Genetic modulation of cognition and emotion must be approached with technical sophistication, compassion, and caution.